Edwards Lifesciences (NYSE:EW) posted fourth-quarter results that fell short of the consensus forecast on Wall Street, but reaffirmed its outlook for 2022.
The Irvine, California-based heart device company yesterday evening reported profits of $335.3 million — or $0.53 per diluted share — on sales of $1.33 billion for the three months ended Dec. 31, 2021, for a bottom-line gain of 8% and sales growth of 12% compared with Q4 2020.
Transcatheter aortic valve replacement (TAVR) sales grew to $872 million for the quarter, up 12% despite the “pronounced impact on hospital resources” in December from the omicron variant of COVID-19, said CEO Mike Mussallem. He cited the delta variant wave in the company’s third-quarter results.
Investors reacted by sending EW shares down more than 5% to $102.97 by afternoon trading today. MassDevice and MDO‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was down slightly.
Get the full story at our sister site, Medical Design & Outsourcing.
This story originally ran on Jan. 26, 2022. Updated Jan. 27 with stock price and analyst comment.